**Document title:** **All Wales Adult Asthma Management and Prescribing Guidelines (update 2023)**

**Closing date: Friday 3 November 2023**

Please fill in your personal details, comments **and** your Declaration of Interests, in the consultation form below. Please type directly into the form and save it with your initials (or other appropriate identifier) before sending it to [awttc@wales.nhs.uk](mailto:AWTTC@wales.nhs.uk).

**Please note:** AWTTC compile all comments received during consultation into a report to be considered by the development group. Each comment will be addressed and any changes to the document that are made as a result will be noted. A summary report, including any comments submitted, will be available on request within 3 weeks of publication of the finished document.

AWTTC reserves the right to summarise comments, where it is deemed appropriate, and to not publish comments if we consider their publication to be unlawful or otherwise inappropriate.

**By submitting your comments, you are agreeing to them being used in line with the above.**

|  |  |
| --- | --- |
| **Name** | Alwyn Fortune |
| **Organisation/Company** | Royal Pharmaceutical Society (RPS) |

**Consultation comments**

Is there anything you would like to see **added** to the *All Wales Adult Asthma Management and Prescribing Guidelines (update 2023)* document?

|  |
| --- |
| There is nothing of note we would like to see added to the guidelines and are supportive of the approach.  We are pleased to see a sustainable green approach to the guidelines, noting that good asthma control is good for the environment and greener due to a reduction in pMDI salbutamol use. The use of SABA Reliever therapy being moved to the ‘less effective (more traditional) regimen supports this agenda.  At the RPS we have developed sustainability policies with inhaler choice being a key component of the ‘improving prescribing and medicines use’ theme. We know metered dose inhalers (MDI) contribute an estimated 3% of the carbon footprint of the NHS in the UK. It is clear there is a significant opportunity to optimise medicines and reduce emissions associated with inhalers.  Pharmacists can review a patient’s diagnosis, inhaler technique, frequency of inhaler use and, if appropriate, switch to a lower carbon inhaler.  We know research has shown that recycling of used inhalers, switching to inhalers with lower propellant levels and encouraging patients to keep track of doses to avoid disposing of half used inhalers and reducing waste can have a positive environmental and cost benefit. We are supportive of an approach which encompasses these principles. |

Is there anything you would like to see **removed** from the *All Wales Adult Asthma Management and Prescribing Guidelines (update 2023)* document?

|  |
| --- |
| N/A |

**Please submit any further comments using the table below.**

| **Page number /section number/ line number** | **Comment** |
| --- | --- |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |

**Declaration of interests**

Do you have any business or personal interests that might be material and relevant to the project or document under consideration?

|  |  |
| --- | --- |
| **Yes** |  |
| **No** |  |

If **yes**, please give details below:

|  |
| --- |
|  |